TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00984516
Drug: Juvidex
Normalized name: Juvidex
DrugBank: Mannose 6-phosphate (DB11848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
Study: NCT00984516
Drug: Juvidex
Normalized name: Juvidex
DrugBank: Mannose 6-phosphate (DB11848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
Study: NCT00984516
Drug: Juvidex
Normalized name: Juvidex
DrugBank: Mannose 6-phosphate (DB11848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
Study: NCT02853864
Drug: 0.0 ng/ml Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine target plasma concentration is 0.0 ng/ml
Study: NCT02853864
Drug: 0.4 ng/ml Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine target plasma concentration is 0.4 ng/ml
Study: NCT02853864
Drug: 0.6 ng/ml Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine target plasma concentration is 0.6 ng/ml
Study: NCT02853864
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
Study: NCT01467479
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet
Study: NCT01467479
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT01467479
Drug: Highly Active Antiretroviral Therapy (HAART)
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
Study: NCT02310789
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150mg administered orally twice daily.
Study: NCT02310789
Drug: β-Adrenergic cocktail
Normalized name: aminophylline and adrenergics
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).
Study: NCT02310789
Drug: Pilocarpine Nitrate 5%
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered subcutaneously using Macroduct sweat stimulator device.
Study: NCT00908921
Drug: GLIMEPIRIDE
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
Study: NCT03136406
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Study: NCT03136406
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03136406
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Study: NCT03282006
Drug: pivmecillinam
Normalized name: pivmecillinam
DrugBank: Pivmecillinam (DB01605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
Study: NCT03576287
Drug: Apremilast Oral Product
Normalized name: apremilast Oral Product
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast
Study: NCT00001662
Drug: CX516 (Ampalex)
Normalized name: CX516
DrugBank: CX516 (DB06247)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00333476
Drug: MSI-1256F (Squalamine Lactate)
Normalized name: morphine sulfate Oral Solution [MSIR]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03404401
Drug: Polyethylene glycol bowel preparation
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bowel preparation
Study: NCT00988208
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg lenalidomide orally once each day on Days 1-14
Study: NCT00988208
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 intravenous docetaxel on Day 1
Study: NCT00988208
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg prednisone orally twice daily on each day of the treatment cycle
Study: NCT01796964
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For intravitreal (IVT) injection
Study: NCT01685359
Drug: Epoetin Alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
Study: NCT00846859
Drug: varenicline (Champix/Chantix)
Normalized name: varenicline Oral Tablet [Chantix]
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).
Study: NCT00846859
Drug: placebo for varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)
Study: NCT00003293
Drug: leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003293
Drug: procarbazine hydrochloride
Normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01597479
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In dPNBs group, we performed ultrasound guided dPNBs on radial and median nerves using low concentration and low volume of long acting local anesthetic (0.125% levobupivacaine, 5 ml per nerve). Using low concentrations of levobupivacaine on target nerves could achieve a prolonged sensitive block in the surgical area without motor block of the hand.
Study: NCT03170388
Drug: IDP-126 Component A
Normalized name: AS01E COMPONENT MPL-A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Component A
Study: NCT03170388
Drug: IDP-126 Component B
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Component B
Study: NCT03170388
Drug: IDP-126 Component C
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Component C
Study: NCT00627471
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
Study: NCT00627471
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG\<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic.
Study: NCT02000531
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg oral dose of erlotinib given once daily
Study: NCT00794417
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered in combination with the other two interventions via intravenous infusion.
Study: NCT00794417
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered in combination with the other two interventions via intravenous infusion.
Study: NCT00794417
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered in combination with the other two interventions via intravenous infusion.
Study: NCT01042535
Drug: 1-methyl-d-tryptophan
Normalized name: 1-methyl-D-tryptophan
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally (PO)
Study: NCT03764735
Drug: Low Dose - SkQ1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SkQ1 Low dose ophthalmic solution
Study: NCT03764735
Drug: High dose - SkQ1
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SkQ1 High Dose ophthalmic solution
Study: NCT03393416
Drug: PD1 antibody
Normalized name: Anti-PD1 / CTLA4 Bispecific Antibody XmAb20717
DrugBank: Vudalimab (DB18833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: PD1 antibody~1mg/kg or 3mg/kg. Administration is conducted in Day1 and Day15. Conducted until disease progression, intolerance or end of study.
Study: NCT00949988
Drug: Dasatinib and Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional
Study: NCT00604084
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
Study: NCT00604084
Drug: Permethrin 5% lotion
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
Study: NCT01253928
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45mg qd for 4 months
Study: NCT01992016
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg given orally twice daily for 1 day (2 doses).
Study: NCT02409186
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/w，d1, week 1-7
Study: NCT02849639
Drug: Scopolamine patch
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.
Study: NCT02409186
Drug: chemoradiotherapy Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45 mg/m2, d1, week 1-7
Study: NCT02409186
Drug: chemoradiotherapy Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2, d1, week 1-7
Study: NCT03353298
Drug: Allopurinol 300 mg
Normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol oral tablets 300 mg given to participants once daily for 9 months
Study: NCT02274948
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin in the form of 500mg tablets were administer to the Metformin group
Study: NCT03207958
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -Given over 1 hour
Study: NCT00583518
Drug: Parathyroid hormone (PTH)
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmenopausal women with primary osteoporosis
Study: NCT00908219
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
Study: NCT00775606
Drug: Lopinavir 400 mg/ritonavir 100 mg
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
Study: NCT00775606
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
Study: NCT01668121
Drug: Budesonide/formoterol Easyhaler
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02278718
Drug: NexoBrid
Normalized name: Nexobrid
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NexoBrid is an enzymatic debriding agent for Eschar Removal.
Study: NCT04158817
Drug: 68Ga-Labeled PSMA
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.
Study: NCT04158817
Drug: Non-labeled PSMA
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be injected with microdose (\<100 ug) of THP-PSMA
Study: NCT00010413
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03093272
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a GnRH agonist
Study: NCT03093272
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone is a corticosteroid
Study: NCT03093272
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
Study: NCT02042885
Drug: OPB-111001
Normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03093272
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
Study: NCT01980342
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
Study: NCT01501110
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
Study: NCT00024388
Drug: DHA-paclitaxel
Normalized name: DHA-paclitaxel
DrugBank: Paclitaxel docosahexaenoic acid (DB05297)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02371421
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02775539
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.
Study: NCT00314782
Drug: ZD4054 (Zibotentan)
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT00314782
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT01352182
Drug: Pioglitazone hydrochloride
Normalized name: Pioglitazone Hydrochloride
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
Study: NCT00672776
Drug: paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02640365
Drug: MM-398
Normalized name: sodium phosphate, dibasic 398 MG
DrugBank: Sodium phosphate, dibasic (DB14502)
Approvals — FDA: no, EMA: no, PMDA: no
Description: unresectable Advanced non-colorectal cancer
Study: NCT02640365
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: unresectable metastatic colorectal cancer
Study: NCT02640365
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: unresectable metastatic colorectal cancer
Study: NCT02640365
Drug: MM-398
Normalized name: sodium phosphate, dibasic 398 MG
DrugBank: Sodium phosphate, dibasic (DB14502)
Approvals — FDA: no, EMA: no, PMDA: no
Description: unresectable metastatic colorectal cancer
Study: NCT02893280
Drug: aspirin, clopidogrel, statin, enoxaparin, streptokinase
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute coronary syndrome treatment
Study: NCT04214665
Drug: Alpha Lipoic acid 600 mg HR film coated tablets
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00610324
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
Study: NCT00610324
Drug: Potassium permanganate
Normalized name: Potassium Permanganate
DrugBank: Potassium permanganate (DB13831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
Study: NCT00612677
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose Regimen: 120 mg/m\^2 on Days 1 every 21 days
Study: NCT00612677
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose Regimen: 500 mg/m\^2 on Days 1 every 21 days
Study: NCT01649947
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.~Prior to receiving paclitaxel, all patients will receive the following premedication:~* Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv \< 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)~* Diphenydramine 50 mg iv (or equivalent) \< 1 hour prior to paclitaxel infusion~* Ranitidine 50 mg iv \< 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)
Study: NCT01649947
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.
Study: NCT00003130
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03417830
Drug: GSK2315698 (CPHPC)
Normalized name: CPHPC
DrugBank: Miridesap (DB13087)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.
Study: NCT00467987
Drug: androgel
Normalized name: AndroGel
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: androgel 1%
Study: NCT01649947
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.
Study: NCT04526652
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evaluating anxiety score in both arms
Study: NCT01649947
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 1 only:~Bevacizumab will be given by IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg. Cycles every 3 weeks for 4-6 Cycles.